Insmed (INSM) Misses Q3 EPS by 12c; Reports Cash and Cash Equivalents of $846.6M
Insmed (NASDAQ: INSM) reported Q3 EPS of ($0.96), $0.12 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $46.8 million versus the consensus estimate of $50.68 million.
For earnings history and earnings-related data on Insmed (INSM) click here.